Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma
Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma
复制标题
DOI：
10.1002/hed.21890
复制
发表时间：
2012-08-01
影响因子：
2.9
通讯作者：
Wang, Hung-Ming
中科院分区：
文献类型：
--
作者：
Hsu, Cheng-Lung;Chang, Kai-Ping;Wang, Hung-Ming
背景：探讨血浆EB病毒(EBV)DNA作为转移性鼻咽癌(NPC)预后新指标的治疗前拷贝数和清除率。方法73例转移性鼻咽癌患者在门诊就诊。用实时定量聚合酶链式反应测定血浆EB病毒DNA浓度和血浆病毒清除率的半衰值。结果治疗3~6个月后评定疗效，总有效率为53.5%。治疗前血浆EBVDNA浓度和血浆EBVDNA清除率的半衰期对治疗反应和总体生存预测有显着影响。在化疗方案中，吉西他滨联合顺铂的疗效优于顺铂加口服UFT和以亚叶酸钙为基础的方案。结论治疗前血浆EBV DNA拷贝数及其清除率是预测鼻咽癌治疗效果的重要指标。(C)2011年威利期刊公司Head Neck，2012年
Background To investigate the pretreatment copy number and the clearance rate of plasma Epstein-Barr virus (EBV) DNA as novel prognostic outcome markers for metastatic nasopharyngeal carcinoma (NPC). Methods Seventy-three patients with metastatic NPC were treated at outpatient department. Plasma EBV DNA concentrations and half-life values of plasma viral clearance rates, were determined by real-time quantitative polymerase chain reaction. Results Treatment response evaluated after 3 to 6 months of treatment showed that the overall response rate was 53.5%. The pretreatment plasma EBV DNA concentrations and the half-life of plasma EBV DNA clearance rates had significant effects on treatment response and overall survival prediction. In the chemotherapy regimen, gemcitabine plus cisplatin had a better treatment outcome than the cisplatin plus oral UFT and calcium folinatebased regimens. Conclusions The pretreatment plasma EBV DNA copy number and their clearance rates are significant predictors for NPC treatment outcome. (c) 2011 Wiley Periodicals, Inc. Head Neck, 2012